[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587128":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":10,"locations":19,"responsibleParty":36,"collaborators":10,"id":38,"slug":10,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Different stages of Alzheimer's disease",null,[12],"Diagnostic Test: Multimodal Ophthalmic Imaging and plasma biomarker",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Multimodal Ophthalmic Imaging and plasma biomarker","Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42\u002F40, p-tau181, p-tau217, NfL and GFAP）.",[9],[20],{"facility":5,"status":21,"city":22,"state":10,"zip":10,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"RECRUITING","Beijing","China",{"type":25,"coordinates":26},"Point",[27,28],116.39723,39.9075,{"lat":28,"lon":27},[31],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Yong an Prof.Sun","CONTACT","83572371","sya@bjmu.edu.cn",{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100587128",false,"NCT06924359","Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease","MOIPAD","Inclusion Criteria:\n\n* Male or female participants aged ≥ 50 years;\n* Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;\n* Inability to cooperate with cognitive assessments;\n* Refusal to undergo blood sampling.","ALL","50 Years",{"count":47,"type":48},200,"ESTIMATED","OBSERVATIONAL","With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).",[52],"Alzheimer's Disease (AD)","2025-04-06",{"date":55,"type":56},"2025-04-11","ACTUAL",{"date":58,"type":56},"2025-03-19",{"date":60,"type":48},"2027-08-31",{"name":5,"class":6},1]